Currently Viewing:
Newsroom
Currently Reading
Payers Have Room for Improvement in Delivering Pain Care, Study Says
June 22, 2018 – Allison Inserro
5 Things to Know About the CREATES Act
June 22, 2018 – Kelly Davio
AJMC® in the Press, June 22, 2018
June 22, 2018 – AJMC Staff
What We're Reading: Health Agencies Could Change; Pandemic Gaps Highlighted; Cigna Seeks to Cut Overdoses
June 22, 2018 – AJMC Staff
Study Compares Cannabis Benefits for Patients With Chronic Pain and Migraine
June 22, 2018 – Alison Rodriguez
Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas
June 22, 2018 – Laura Joszt
Neurofilament Light Prevalence Predicts Disease Progression in RRMS
June 21, 2018 – Samantha DiGrande
Tracking Medicaid Expansion
June 21, 2018 – AJMC Staff
FDA Warns Efficacy Concerns in Some Patients Taking Keytruda, Tecentriq
June 21, 2018 – Samantha DiGrande

Long-Term Oxygen Therapy Can Improve Survival in Patients With Oxygen-Dependent COPD

Surabhi Dangi-Garimella, PhD
A new study has shown that long-term oxygen therapy in patients with severe alpha-1 antitrypsin deficiency can improve survival; however, their outcomes do not improve following lung-transplantation.
Patients with severe alpha-1 antitrypsin deficiency (AATD) are at an increased risk of developing chronic obstructive pulmonary disease (COPD). Now, a new study has shown that long-term oxygen therapy (LTOT) in this patient population can improve survival; however, their outcomes do not improve following lung-transplantation.

Found in 1% to 2% of patients with COPD, the PiZZ phenotype, which is characteristic of AATD, is a significant cause for COPD. Along with vaccinations, bronchodilators, rehabilitation, and surgical interventions in selected patients, LTOT is also a treatment option.

In the current study, published in the International Journal of COPD, 14,644 patients who were on LTOT due to their COPD were enrolled. Patients with AATD, the authors note, tended to be younger, male, and never smokers. The study used data from the Swedish National Registry for Respiratory Failure for the period between January 1, 1987, and June 30, 2015.

At a median follow-up of 1.6 years on LTOT, patients without severe AATD had higher mortality (hazard ratio [HR] 1.53; 95% CI, 1.24–1.88)—there were 201 (71%) deaths among patients with AATD and 12,354 (86%) deaths among patients without AATD. The median survival was 1.9 years (95% CI, 1.8–1.9) overall; patients with AATD had a significantly longer survival (3.5 years; 95% CI, 2.8–4.3) than patients without AATD (1.9 years; 95% CI, 1.8–1.9; P<.001). This was after normalizing for age, gender, smoking status, body mass index, performance status, level of hypoxemia, and comorbidities. Cardiovascular deaths were higher in patients without AATD (16% compared with 6%; P<.001).

Of the 171 patients who underwent a lung transplant during the follow-up period, 53 (31%) had severe AATD. At a 4.4 year median follow-up after a lung transplant, 103 patients died, 36 (35%) of whom had severe AATD. While a higher proportion of AATD patients had a lung transplant—19%, compared with 1% of those without AATD—survival was similar for both populations. Higher age, according to the authors, was the only significant predictor of death after a lung transplant in this population.

Based on their findings, the authors conclude that patients with severe AATD have better survival in oxygen-dependent COPD, but prognosis following a lung transplant is independent of their AATD status.

Reference

Ekstrom M, Tanash H. Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status. Int J COPD. 2017;12: 3281-3287.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!